The clause even extends the internet specifically in that plaintiffs and attorneys "will not maintain and instead will discontinue any website references to Paxil discontinuation or withdrawal."

And, it says, they "agree to refrain from any future internet postings regarding Paxil discontinuation or withdrawal."

Paragraph 5 of the lawsuit's complaint says that over a 2 years period, "plaintiffs' attorneys have been individually contacted by approximately 500 Paxil withdrawal victims."

And, the pain and suffering experienced by each individual is the direct result of Glaxo's "failure to warn users of Paxil's addictive nature, the drug's inducement of physical or psychologic dependency, and its infliction of dependency/withdrawal syndrome when the patient's Paxil dosage is reduced or terminated," the complaint states.

Paragraph 16, lists withdrawal reactions that "can summed up as one or more of the following complaints: jolting electric "zaps," dizziness, light headedness, vertigo, incoordination, gait disturbances, sweating, extreme nausea, vomiting, high fever, abdominal discomfort, flu symptoms, anorexia, diarrhea, agitation, tremulousness, irritability, aggression, sleep disturbance, nightmares, tremor, confusion, memory and concentration difficulties, lethargy, malaise, weakness, fatigue, paraesthesias, ataxia, and/or myalgia."

Paragraph 7, says: "These reactions are "unexpected" to the victims and even their physicians because the manufacturer has deliberately failed to properly warn of this." 

"Both physician and patient unwittingly use Paxil without knowing the drug's addictive traits," the complaint says.

Paragraph 8, charges that because Glaxo has suppressed the information, patients and physicians are fooled into thinking that the reactions are caused by another condition, such as relapse into depression, thus prompting incorrect and unnecessary medical treatment, including increased dosages of Paxil. 

Both physician and patient unwittingly use Paxil without knowing the drug's addictive traits,

Starting in December 2001, Glaxo finally added a minimizing precaution to Paxil's label of some possible "discontinuation" side effects affecting "2 percent or greater" of patients based on studies. 

However, documents reveal that Glaxo has always known about the withdrawal syndrome. For instance, in 1993, in a report that occurred 5 months after Paxil arrived on the market, Stoker and Eric noted Paxil withdrawal at the American Psychiatric Association's annual meeting in San Francisco, May 22-27, 1993. 

The authors of the study conducted 2 week tapering off periods for 186 patients in 6 to 12 week doubled blinded comparative studies. Low dose and high dose groups were studied. Paxil's low dose group actually did worse than the high dose group, suffering 42% withdrawal rate, compared to 38% in the high dose group.  And, both occurred even though the tapering off regime was initiated during dosage reduction. 

instead of 'withdrawal syndrome,' which implies addictive properties, try to refer to this phenomenon as 'discontinuation symptoms

A fact well-evidenced in internal company documents. A previously suppressed, May 1, 1997, Glaxo memo to, "Paxil Selling Team," on the "discontinuation syndrome," defines the withdrawal syndrome as, "a class effect that can occur when an SSRI is stopped abruptly. Symptoms may include asthenia, flu-like symptoms, fatigue, dizziness, nausea, and sleep disturbances (insomnia, vivid dreams or nightmares)." 

However, the memo instructs Glaxo sales representatives to avoid using the term and says: "instead of 'withdrawal syndrome,' which implies addictive properties, try to refer to this phenomenon as 'discontinuation symptoms." 

Eight months later, in a December 1, 1997, "Business Plan Guide," sales representatives were instructed to "minimize concerns surrounding discontinuation symptoms," and told to explain to doctors that the "discontinuation incident rate is two in 1,000 patients." 

However, according to a 1997 review, one study found that 25% of patients experienced at least one discontinuation symptoms, verses 5.9% taking a placebo. In another study of patients with major depression, 42% experienced at least 1 discontinuation symptom. 

Another internal memo kept hidden with a protective order, states:  "Discontinuation: why this is an issue," followed by, "'97 Seroxat/Paxil sales to end Sept already exceed $1 Billion". 

This particular memo carries a cartoon-like picture of a big black money-bag.